Table 2.
Humoral response rates by SARS-CoV-2 specific antibody levels of the study population and comparison between previously infected and previously uninfected.
| Variable | Total (n = 268) | Previously Infected (n = 121) | Not Previously Infected (n = 147) | p-Value |
|---|---|---|---|---|
| IgM/IgG SARS-CoV-2 S1 (UI/mL) * | ||||
| - Baseline | 3.3 (0.4–23.5) | 23.8 (10.3–85.3) | 0.95 (0.4–1.75) | <0.001 a |
| - 21 days after first dose | 21.7 (5.8–64.1) | 65.45 (44.6–102) | 8.4 (3.7–17.2) | <0.001 a |
| - 21 days after second dose | 66.1 (35.45–105.7) | 82.5 (57.9–110.9) | 49.5 (25.7–89.8) | <0.001 a |
| IgM/IgG/IgA anti-SARS-CoV-2 N (S/Co) *(IQR) | ||||
| - Baseline | 0.1 (0.1–24.65) | 25.9 (9.1–68.5) | 0.1 (0.1–0.1) | <0.001 a |
| - 21 days after first dose | 0.7 (0.1–128.1) | 135.6 (85.8–190.3) | 0.1 (0.1–0.2) | <0.001 a |
| - 21 days after second dose | 37.4 (2.75–155.35) | 159.7 (93.8–211.4) | 2.9 (0.5–7.8) | <0.001 a |
| Ab neutralization cPass™ (%) * (IQR) | ||||
| - 21 days after second dose | 88.1 (68–96.3) | 96.4 (92.4–97.1) | 73.5 (53.9–85.2) | <0.001 a |
| - 90 days after second dose | 72.4 (45.1–94.3) | 94.3 (82.9–96.1) | 45.6 (30.85–65.7) | <0.001 a |
| - 180 days after second dose | 63.6 (27.8–92.2) | 88.5 (72.4–95.8) | 28.15 (16.9–43.55) | <0.001 a |
| Elecsys® anti-SARS-CoV-2 S (UI/mL) * (IQR) | ||||
| - 21 days after second dose | 293.45 (92.75–1275) | 1288 (715.9–2334) | 117.4 (48.7–222.8) | <0.001 a |
| - 90 days after second dose | 187.1 (49–737.4) | 714.7 (414–1347) | 49.95 (28.05–101.25) | <0.001 a |
| - 180 days after second dose | 296.2 (63.9–782.1) | 558.2 (356.8–1135) | 64.2 (29.4–146.5) | <0.001 a |
* Median and interquartile range, a U-Mann–Whitney, IQR: Interquartile range.